Trial reportAllergy2026
Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma.
Trial report in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02573233 (An Exploratory, Double-blind, Placebo-controlled Study of the Effects of Dupilumab on Airway Inflammation of Adults With Persistent Asthma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Exploratory, Double-blind, Placebo-controlled Study of the Effects of Dupilumab on Airway Inflammation of Adults With Persistent Asthma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundBiologics targeting type 2 cytokines can inhibit airway inflammation and improve lung function in moderate-to-severe asthma; however, their impact on airway mucosal inflammatory cells is unclear. This study assessed the effects of dupilumab on airway mucosal and systemic inflammation, and related gene expression in patients with persistent asthma.
methodsIn the phase 2a EXPEDITION study (NCT02573233), patients aged 18-65 years were randomised to add-on dupilumab 300 mg (n = 20) or placebo (n = 22) every 2 weeks for 12 weeks. Pre- and post-treatment bronchial biopsies, bronchial brushings, bronchoalveolar lavage (BAL) fluid and blood samples were collected. Clinical and patient-reported outcomes, gene expression, type 2 biomarkers and safety outcomes were assessed.
resultsDupilumab versus placebo improved lung function and asthma control. No significant changes in eosinophils, mast cells or type 2 helper cells were observed in bronchial biopsies. Downregulation of M2 macrophage- and eosinophil-associated gene sets was observed in BAL and brushing samples after dupilumab. Dupilumab decreased multiple circulating type 2 biomarkers in peripheral blood (p
conclusionDupilumab improved lung function and asthma control while reducing circulating type 2 biomarkers. No measurable impact was observed on type 2-associated inflammatory cell numbers in airway bronchial biopsies; however, dupilumab modulated the expression of inflammation-associated gene sets. These findings provide cellular and molecular data that may explain dupilumab-driven mechanisms of improved lung function in patients with type 2 asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.